Document is current
Any future updates will be listed below
-
Authors
Karpinets, Tatiana V.
Mitani, Yoshitsugu
Chang, Chia-Chi
Wu, Xiaogang
Song, Xingzhi
Flores, Ivonne I.
McDaniel, Lauren K.
Hoballah, Yasmine M.
Veguilla, Fabiana J.
Ferrarotto, Renata
Colbert, Lauren E.
Ajami, Nadim J.
Jenq, Robert R.
Zhang, Jianhua
Futreal, Andrew P.
El-Naggar, Adel K.
-
Funding
Funding for this research was provided by:
Adenoid Cystic Carcinoma Research Foundation
MD Anderson Cancer Center Moonshot program
- License Information
-
More Information
Article History
Received: 26 March 2024
Accepted: 25 June 2024
First Online: 15 July 2024
Competing interests
: Dr. Renata Ferrarotto discloses research funding in the past 2 years from ISA Therapeutics, Merck, Ayala Pharmaceuticals, Viracta, Gilead, Seagen, Prelude Therapeutics, and Sanofi. She also discloses Consulting/advisory role in Coherus Bioscience, Eisai Medical Research, Elevar Therapeutics, Prelude Therapeutics, Regeneron Pharmaceuticals, Remix Therapeutics, Sanofi-aventis, Answers in CME, and Labcorp Drug Development. All other authors do not have any competing interest.
